Evixapodlin (PD-1/ PD-L1-in 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. Evixapodlin has anti-cancer and anti-virus properties.
Relacorilant is a selective, oral bioeffective glucocorticoid receptor antagonist (Ki of 7.2 nM in HepG2 TAT assay and 12,81.2 nM in rat, human and monkey glucocorticoid receptor in cell-based assay). Relacorilant can be used in studies of Cushing's syndrome.
Relacorilant is a selective, oral bioeffective glucocorticoid receptor antagonist (Ki of 7.2 nM in HepG2 TAT assay and 12,81.2 nM in rat, human and monkey glucocorticoid receptor in cell-based assay). Relacorilant can be used in studies of Cushing's syndrome.
Navoximod (GDC-0919; Nlg-919) is an effective IDO (indoleamine-(2,3)-dioxygenase) inhibitor with Ki/EC50 of 7 nM/75 nM respectively.
Navoximod (GDC-0919; Nlg-919) is an effective IDO (indoleamine-(2,3)-dioxygenase) inhibitor with Ki/EC50 of 7 nM/75 nM respectively.
DBCO-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
DBCO-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
AT7519 (AT7519M) TFA as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and
AT7519 (AT7519M) TFA as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/
Octreotide is a somatostatin analog that binds to the somatostatin receptor, mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production.
Argipressin (Arg8-vasopressin) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a Kd value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1.